Nuo Therapeutics CSO/COO gets 65,000 stock options

Nuo Therapeutics, Inc. reported that CSO/COO Peter Clausen received a grant of options to purchase 65,000 shares of common stock.

Rhea-AI Filing Summary

Nuo Therapeutics, Inc. reported that CSO/COO Peter Clausen received a grant of options to purchase 65,000 shares of common stock. The options have an exercise price of $1.01 per share and expire on June 29, 2036.

According to the disclosure, one third of these options become exercisable as of June 30, 2027, with the remaining balance vesting quarterly over the following two years. After this grant, Clausen holds options for 65,000 underlying shares directly, reflecting a compensation-related award rather than an open-market trade.

Insider Trade Summary

Grant/Award: 65,000 shares

Grant/Award 1 txn

Insider CLAUSEN PETER

Role CSO/COO

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase common stock	65,000	$0.00	$0.00

Holdings After Transaction: Option to purchase common stock — 65,000 contracts (Direct)

Footnotes (1)

1. F1. One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly over the subsequent two years.

Key Figures

Option grant size: 65,000 options Exercise price: $1.01 per share Expiration date: June 29, 2036 +2 more

5 metrics

Option grant size 65,000 options Options to purchase common stock granted to CSO/COO

Exercise price $1.01 per share Conversion or exercise price of the options

Expiration date June 29, 2036 Option expiration for the 65,000-share grant

Underlying shares 65,000 shares Common stock underlying the option award

Initial vesting date June 30, 2027 One third of options exercisable as of this date

Key Terms

Option to purchase common stock, Grant, award, or other acquisition, exercise price, vest quarterly, +1 more

5 terms

Option to purchase common stock financial

"security_title: Option to purchase common stock"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 1.0100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest quarterly financial

"the balance vest quarterly over the subsequent two years"

derivative financial

"transaction_type: derivative"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nuo Therapeutics (AURX) report for Peter Clausen?

Nuo Therapeutics reported that CSO/COO Peter Clausen received a grant of options to purchase 65,000 shares of common stock. This award is a compensation-related option grant, not an open-market stock purchase or sale.

What is the exercise price of Peter Clausen’s new stock options at Nuo Therapeutics (AURX)?

The options granted to Peter Clausen have an exercise price of $1.01 per share. This is the price he must pay per share to convert the options into common stock once they vest and are exercised.

When do Peter Clausen’s Nuo Therapeutics (AURX) stock options vest?

One third of Peter Clausen’s options are exercisable as of June 30, 2027. The remaining options vest quarterly over the subsequent two years, creating a multi-year incentive tied to continued service.

When do the newly granted Nuo Therapeutics (AURX) options to Peter Clausen expire?

The options granted to Peter Clausen expire on June 29, 2036. After this expiration date, any unexercised options will lapse and can no longer be converted into shares of Nuo Therapeutics common stock.

How many Nuo Therapeutics (AURX) options does Peter Clausen hold after this Form 4?

Following this transaction, Peter Clausen holds options covering 65,000 shares of Nuo Therapeutics common stock. The filing shows this full amount as his derivative holdings after the grant, all held in direct ownership form.

Is Peter Clausen’s Nuo Therapeutics (AURX) Form 4 a stock purchase or sale?

The Form 4 reports a grant of options as compensation, not a stock purchase or sale. The transaction code is “A” for grant, and no open-market buying or selling of Nuo Therapeutics common shares is disclosed in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 09:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CLAUSEN PETER

(Last) (First) (Middle)

C/O NUO THERAPEUTICS, INC.

8285 EL RIO, SUITE190

(Street)

HOUSTON TEXAS 77054

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuo Therapeutics, Inc. [ AURX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CSO/COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$1.01	06/29/2026		A		65,000		(1)	06/29/2036	Common Stock	65,000	$0	65,000	D

Explanation of Responses:

1. One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly over the subsequent two years.

	/s/ David Jorden, attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)